Current Issue : April - June Volume : 2019 Issue Number : 2 Articles : 6 Articles
Aims: To investigate the diagnostic value of fecal calprotectin (FC) determined\nby a new immunofluorescence assay-fluorescence enzyme immunoassay\n(FEIA) in patient with inflammatory bowel disease (IBD) or functional\nbowel disease, compared with the typical ELISA kit. Methods: FC was determined\nsimultaneously by FEIA and an ELISA kit in 26 patients with functional\nbowel disease and 77 patients with IBD. We compared the difference of\nFC levels between patients with IBD and patients with functional bowel disease.\nReceiver operating characteristics curve (ROC) was constructed to obtain\nthe optimal cut-off value of FC for distinguishing IBD from functional\nbowel disease and the corresponding sensitivity and specificity. Results: The\nmedian FC levels of patients with IBD in clinical active stage or clinical remission\nstage was significantly higher than that of patients with functional\nbowel disease. The median FC levels of patients with IBD in clinical active\nstage, IBD in clinical remission stage and functional bowel disease were as\nfollow: 699.91....................
Zinc deficiency is frequently observed in chronic liver diseases. However, no studies\nhave focused on the zinc status in chronic hepatitis C (HCV)-infected patients receiving direct-acting\nantiviral agents (DAAs). In this retrospective study, we assessed the serum zinc status in DAA-treated\nHCV patients with sustained virologic response for over two years (Zn-2y). Ninety-five patients\nwere enrolled, whose baseline characteristics and blood parameters at DAA therapy initiation\nwere collected....
NA...
Background: Pediatric patients always suffer from chronic pancreatitis (CP), especially those with steatorrhea. This\nstudy aimed to identify the incidence of and risk factors for steatorrhea in pediatric CP. To our best knowledge,\nthere is no pediatric study to document the natural history of steatorrhea in CP.\nMethods: CP patients admitted to our center from January 2000 to December 2013 were enrolled. Patients were\nassigned to the pediatric (< 18 years old) and adult group according to their age at onset of CP. Cumulative rates\nof steatorrhea in both groups were calculated. Risk factors for both groups were identified, respectively.\nResults: The median follow-up duration for the whole cohort was 7.6 years. In a total of 2153 patients, 13.5% of\nthem were pediatrics. The mean age at the onset and the diagnosis of CP in pediatrics were 11.622 and 19.727,\nrespectively. Steatorrhea was detected in 46 patients (46/291, 15.8%) in the pediatric group and in 447 patients\n(447/1862, 24.0%) in the adult group. Age at the onset of CP (hazard ratio [HR], 1.121), diabetes mellitus (DM, HR,\n51.140), and severe acute pancreatitis (SAP, HR, 13.946) was identified risk factor for steatorrhea in the pediatric\ngroup.\nConclusions: Age at the onset of CP, DM and SAP were identified risk factors for the development of steatorrhea\nin pediatric CP patients. The high-risk populations were suggested to be followed up closely. They may benefit\nfrom a full adequate pancreatic exocrine replacement therapy....
Background: Hepatitis B virus and Hepatitis C virus infection is one of the\npublic health problems in Egypt. So we aimed to evaluate the efficacy of serum\nosteopontin as predictor of hepatic fibrosis regression and virological\nresponse in patients with chronic HBV or HCV infection. Methods: This\nstudy has been conducted on 74 HBeAg posoitive chronic HBV infection, 74\nchronic HCV infection and 74 healthy controls. HBV patients treated with\nEntecavir. HCV patients treated with sofosbuvir, daclatasvir with or without\nribavirin. One year post HBeAg seroconversion and 3 months after end of\nregular antiviral treatment for patients with chronic HBV and chronic HCV\ninfection respectively, hepatic condition was reevaluated. Results: 14.9% of\npatients with HBV, failed to achieve undetectable HBV DNA or HBeAg seroconversion\nand 2.7% of patients with HCV infection, failed to achieve SVR.\nIn chronic HBV, pretreatment high serum osteopontin predict failure of virological\nresponse and hepatic fibrosis regression at a cutoff > 115.5, with\n90.91% sensitivity, 82.54% specificity. Also high degree of liver stiffness predicts\nfailure of hepatic fibrosis regression at a cutoff > 8.7, with 81.8% sensitivity,\n73% specificity. Conclusions: In chronic HBV infection low osteopontin\npredicts good virological response and hepatic fibrosis regression. But it\nhas no role in predicting SVR or hepatic fibrosis regression in chronic HCV\ninfected patients....
Background: This study investigated the relationship between liver stiffness and carotid artery elasticity in patients\nwith chronic viral hepatitis. We used an acoustic radiation force impulse (ARFI) technique to measure stiffness, and\na radio frequency (RF) vascular quantitative ultrasound technique to measure changes in common carotid artery\nelasticity and vascular function.\nMethods: Two-hundred seventeen patients with chronic viral hepatitis caused by either hepatitis B virus (HBV) or\nhepatitis C virus (HCV) were enrolled. We divided the patients into two groups, one comprising 147 patients with\nchronic hepatitis B (CHB) (98 men and 49 women, average age................
Loading....